Compare VCEL & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | GRDN |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | 3600 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 1996 | N/A |
| Metric | VCEL | GRDN |
|---|---|---|
| Price | $46.85 | $40.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $57.75 | $40.60 |
| AVG Volume (30 Days) | ★ 704.3K | 464.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.40 | N/A |
| Revenue Next Year | $18.24 | $7.63 |
| P/E Ratio | ★ N/A | $117.77 |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $19.30 |
| 52 Week High | $48.75 | $44.00 |
| Indicator | VCEL | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 62.66 | 49.97 |
| Support Level | $32.47 | $38.49 |
| Resistance Level | N/A | $40.49 |
| Average True Range (ATR) | 1.76 | 1.79 |
| MACD | -0.21 | -0.19 |
| Stochastic Oscillator | 61.88 | 36.35 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.